Greenphire, LLC

Greenphire, LLC, based in the US, specializes in providing innovative technology solutions that streamline clinical trial management and enhance patient engagement for pharmaceutical companies and research organizations. Greenphire, LLC was founded in 2008 and focuses on optimizing clinical trial processes through advanced technology. The company has not undergone significant strategy changes or business pivots since its inception. Its headquarters are located in the US, and John Samar serves as the founder while Jim Murphy is the current CEO.

In January 2025, Greenphire, LLC was involved in a merger with Suvoda LLC, a portfolio company of LLR Partners, although financial terms were not disclosed. The most recent funding round was a Series A round in which USD 1. 50 mn was raised, led by FirstMark Capital, contributing to a total capital raised of USD 1. 50 mn.

Greenphire, LLC offers a comprehensive suite of patient-centric clinical trial technology solutions designed to improve trial management and execution. These services include Interactive Response Technology (IRT), electronic Clinical Outcome Assessment (eCOA), and eConsent solutions, which facilitate patient enrollment, data collection, and regulatory compliance. The company caters to pharmaceutical companies, Contract Research Organizations (CROs), and academic institutions across North America, Europe, and Asia, reinforcing its significant global presence in enhancing the clinical trial experience. Greenphire, LLC implements a business-to-business (B2B) revenue model, collaborating with pharmaceutical companies, CROs, and research institutions.

Clients typically engage through subscription agreements for the software solutions, which are priced based on trial scale and specific service needs. The company collects annual fees for software access along with implementation and ongoing support services. Its flagship offerings, such as the Interactive Response Technology (IRT) and eCOA solutions, play a crucial role in the revenue structure by improving operational efficiency and patient engagement. In January 2025, Greenphire, LLC will merge with Suvoda LLC to enhance its patient services and product capabilities.

This strategic move aims to expand their offerings and improve clinical trial efficiency. The combined entity plans to leverage recent funding to support this integration and develop upcoming innovative solutions while targeting expansion into new geographic markets. The company is expected to focus on broadening its reach in Europe and Asia to serve an even larger client base.